<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Prednisone - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Prednisone</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Endocrine / Metabolic / Antidotes</div>
      <h1>Prednisone</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Prednisone 50mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Acute asthma exacerbation (adult)</strong>
            <ul>
              <li>50 mg PO once daily for at least 5 days (course length per protocol/clinical response)</li>
            </ul>
          </li>
          <li><strong>Acute COPD exacerbation (adult)</strong>
            <ul>
              <li>40 mg PO once daily for 5 days (if only 50 mg tablets are available onboard, 50 mg PO daily is often used in practice; use local guidance)</li>
            </ul>
          </li>
          <li><strong>Severe allergic reaction (adjunct; not first-line for anaphylaxis)</strong>
            <ul>
              <li>50 mg PO once daily for a short course (e.g., 3–5 days) if used; reassess</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Acute asthma exacerbation</li>
          <li>Acute COPD exacerbation</li>
          <li>Other inflammatory/allergic conditions where a short course systemic corticosteroid is appropriate (provider-directed)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to prednisone or formulation components</li>
          <li>Active, untreated serious infection: steroids may worsen/obscure infection (use risk–benefit and reassess frequently)</li>
          <li><strong>Caution (common onboard relevance):</strong>
            <ul>
              <li>Diabetes (hyperglycemia)</li>
              <li>Psychiatric history (mood changes, agitation, insomnia)</li>
              <li>Hypertension/heart failure (fluid retention)</li>
              <li>Peptic ulcer/GI bleeding risk (especially with NSAIDs/ASA)</li>
              <li>Immunosuppressed states / recent live vaccines (provider-directed)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Hyperglycemia</li>
          <li>Mood changes (irritability/euphoria), insomnia</li>
          <li>GI upset/dyspepsia</li>
          <li>Fluid retention, increased appetite</li>
          <li>Increased infection risk (dose/duration dependent)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; take with food if possible to reduce GI upset</li>
          <li>Prefer morning dosing to reduce insomnia (operationally)</li>
          <li>Short "burst" courses usually do NOT require tapering; tapering may be needed if prolonged use or chronic steroid exposure (use local guidance)</li>
          <li>Avoid abrupt discontinuation in patients on chronic steroids (adrenal suppression risk)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom response (respiratory status, peak flow if used locally, work of breathing)</li>
          <li>Blood glucose in diabetics or those at risk</li>
          <li>Mood/sleep disturbance</li>
          <li>Signs of infection or clinical deterioration</li>
          <li>GI symptoms/bleeding risk if combined with NSAIDs/ASA</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Stock is 50 mg tablets: plan dosing around this strength and document dose/time clearly to avoid "partial tab" confusion</li>
          <li>If infection is plausible (e.g., pneumonia), reassess frequently and avoid anchoring on "inflammation-only"</li>
          <li>Consider GI protection strategy and bleeding risk if concurrent NSAIDs/ASA are being used</li>
          <li>Document start date, planned duration, and stop date to prevent unintended prolonged courses</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (APO-PREDNISONE; prednisone): <a href="https://pdf.hres.ca/dpd_pm/00080333.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00080333.PDF</a></li>
          <li>Canadian Thoracic Society asthma algorithm (includes prednisone burst dosing): <a href="https://cts-sct.ca/wp-content/uploads/2018/07/5156_THOR-Asthma-sj_0318_11.875x9-en-web.pdf" target="_blank">https://cts-sct.ca/wp-content/uploads/2018/07/5156_THOR-Asthma-sj_0318_11.875x9-en-web.pdf</a></li>
          <li>BC guideline (COPD; systemic steroid dosing): <a href="https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/copd" target="_blank">https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/copd</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
